BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Janssen-Cilag International NV 

1, rue Camille Desmoulins
TSA 91003
Issy-les-Moulineaux  Cedex  92787  France
Phone: 33-1-5500-4500 Fax: 33-1-5500-2885


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Janssen-Cilag International NV (JNJ) Release: VOKANAMET™ (Canagliflozin And Metformin Fixed Dose Combination) Receives Positive CHMP Opinion Recommending Approval In The European Union For The Treatment Of Adults With Type 2 Diabetes[1] 2/21/2014 8:45:33 AM    More...
Janssen-Cilag International NV (JNJ)'s INVOKANA™ Wins Approval In The EU For Type 2 Diabetes Patients 11/22/2013 6:25:43 AM    More...
Janssen-Cilag International NV (JNJ) Release: New Marketing Authorisation Application Submitted to European Medicines Agency for Ibrutinib for the Treatment of Two Forms of Blood Cancer 10/30/2013 7:29:36 AM    More...
Janssen-Cilag International NV (JNJ) Submits Marketing Authorisation Application to European Medicines Agency for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir With Cobicistat 10/15/2013 9:29:02 AM    More...
Janssen-Cilag International NV (JNJ) Release: New and Long-Term Use Results for Canagliflozin to be Presented at European Association for the Study of Diabetes Annual Meeting 9/18/2013 10:09:49 AM    More...
European Commission (EC) Approves Janssen-Cilag International NV (JNJ)'s VELCADE® as a Frontline Induction Therapy Before Stem Cell Transplantation 8/8/2013 6:56:56 AM    More...
CHMP Gives a Positive Opinion for the Use of Janssen-Cilag International NV (JNJ)'s VELCADE® as Retreatment and for Frontline Induction Therapy Before Stem Cell Transplantation 6/28/2013 9:35:09 AM    More...
Johnson & Johnson (JNJ)'s Janssen-Cilag International NV (JNJ) Gets EC Approval for DACOGEN in AML 10/1/2012 7:54:01 AM    More...
Janssen-Cilag International NV (JNJ)'s Subcutaneous VELCADE® Approved in the EU for the Treatment of Multiple Myeloma 9/28/2012 7:21:18 AM    More...
Janssen-Cilag International NV (JNJ) Submits European Marketing Authorisation Application for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline 8/31/2012 9:28:14 AM    More...
123